With this agreement, the Spanish biotechnology firm, headquartered in the Parc Cientific de Barcelona and with additional research centres in Barcelona, Valencia and Santiago de Compostela, launches its sales drive into the North American market with clear intentions for sales development of other products. Annual sales turnover is forecast to be 1.5m US dollars, once the product is successfully introduced. <\/p>\n
The agreement allows for Advancell to cede its innovative technology to ADMEcell who will manufacture and sell the reagent in the North American market. This firm is based in San Francisco Bay Area and was founded in 2008 by Sandy Koshkin and Matt Pourfarzaneh – two entrepreneurs with more than twenty years of experience in the reagent field. <\/p>\n
CacoReadyTM,<\/sup> has already been evaluated in USA by a number of pharmaceutical companies. Developed by Advancell CacoReadyTM is designed as a tool to optimize time and costs in the evaluation process of intestinal absorption of compounds. It employs a proprietary technology based on a unique transportation method for ready-to-use live cells. This is achieved using a semi-solid medium offering multiple benefits over transport in liquid form, where the cell quality deteriorates, and also over the more traditional but complicated and expensive transport method of frozen cells, used by the majority of biotechnology firms. <\/p>\n